Status: Recruiting
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Hudson BiotechUpdated: Feb 27, 2026Locations: 1
Eligibility criteria
Adults aged 18-65 years able to provide informed consent. [+4]
Segmental vitiligo as the predominant type, or rapidly progressive disease withi... [+8]